[68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors
European Journal of Nuclear Medicine and Molecular Imaging · 2025-10 · 52 (12) · 4547-4557
DOI: 10.1007/s00259-025-07326-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 09.05.2025. Verfasst von Donglang Jiang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, 200040, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Antigens, Neoplasm, Cell Adhesion Molecules, Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: STI2030-Major Projects.
Abstract (Originalsprache)
PURPOSE: Gallium-68 (68Ga)-labeled [68Ga]Ga-NOTA-T4 immuno-positron emission tomography (immunoPET) holds great promise as a non-invasive technique for visualizing the expression of trophoblast cell-surface antigen 2 (TROP2). This approach may potentially assist in making clinical decisions regarding TROP2-targeted therapies. The present study aims to evaluate the utility of [68Ga]Ga-NOTA-T4 PET/CT in detecting TROP2 expression levels, diagnosing primary tumors and metastatic lesions. Additionally, it conducts a direct comparison with fluorine-18-labeled fluorodeoxyglucose ([18F]FDG) PET/CT. METHODS: Participants with solid tumors who underwent [68Ga]Ga-NOTA-T4 PET/CT scans were prospectively recruited between October 2023 and August 2024. A subset of these participants also received [18F]FDG PET/CT. The uptake in physiological organs was quantified using the mean standardized uptake value (SUVmean). Positive lesions were identified through visual assessments and further quantified using the maximum standardized uptake value (SUVmax) and the target-to-background ratio (TBR). The TBR was calculated by dividing the SUVmax of the lesion by the SUVmean of the background, where the brain background was used for cerebral lesions and the blood pool for other lesions. TROP2 expression levels were evaluated via immunohistochemical (IHC) tumor proportion score (TPS). Biodistribution, lesion detectability, and the correlation with TROP2 were analyzed for both tracers using appropriate statistical methods. RESULTS: A total of 26 patients (mean age: 63 ± 10 years; 13 females) were included in the study. [68Ga]Ga-NOTA-T4 demonstrated high uptake in the kidneys, pancreas, thyroid, and submaxillary gland, while showing low uptake in the brain, muscle, and bone. Both tracers successfully detected all 19 primary/recurrent tumors. However, [68Ga]Ga-NOTA-T4 presented lower SUVmax and TBR compared to [18F]FDG (1.93 [1.36, 2.58] vs. 11.37 [6.45, 13.15], P < 0.001; 2.83 [2.17, 3.74] vs. 6.95 [5.24, 11.27], P = 0.03, respectively). [68Ga]Ga-NOTA-T4 identified fewer suspected metastases but detected two brain metastases that were missed by [18F]FDG. TROP2 TPS was positively correlated with [68Ga]Ga-NOTA-T4 SUVmax (r = 0.85, P = 0.002) and TBR (r = 0.66, P = 0.030), while no significant correlation was observed for [18F]FDG. CONCLUSION: [68Ga]Ga-NOTA-T4 PET/CT emerges as a promising non-invasive tool for assessing TROP2 expression levels and diagnosing solid tumors. In certain specific cases, it exhibits potential advantages over [18F]FDG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, 200040, China.
- Department of Oncology, Huashan Hospital, Fudan University, Shanghai, 200040, China.
- Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
- Central Research Institute United Imaging Healthcare Group Co, Ltd, Shanghai, 201807, China.
- Department of Pathology, Huashan Hospital, Fudan University, Shanghai, 200040, China.
- Department of Rehabilitation, Huashan Hospital, Fudan University, Shanghai, 200040, China.
ORCID-Profile: Fang Xie
Förderung
- STI2030-Major Projects
Zitieren
APA
Jiang, D., Chu, Z., Wu, Y., Zhang, Y., Liu, Y., Ge, Q., Gu, Y., Du, Z., Cheng, Y., Xu, X., Huang, Y., Xu, D., Guan, Y., Wei, W., & Xie, F. (2025). [68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors. European Journal of Nuclear Medicine and Molecular Imaging, 52(12), 4547-4557. https://doi.org/10.1007/s00259-025-07326-8
Vancouver
Jiang D, Chu Z, Wu Y, Zhang Y, Liu Y, Ge Q, et al. [68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(12):4547-4557. doi:10.1007/s00259-025-07326-8
BibTeX
@article{Jiang2025,
author = {Jiang, Donglang and Chu, Zhaohui and Wu, Yanfei and Zhang, You and Liu, Yao and Ge, Qi and Gu, Yue and Du, Zunguo and Cheng, Yuanyuan and Xu, Xiwen and Huang, Yuan and Xu, Dong and Guan, Yihui and Wei, Weijun and Xie, Fang},
title = {[68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
volume = {52},
number = {12},
pages = {4547--4557},
doi = {10.1007/s00259-025-07326-8}
}
EUVIMED